RB1 mutation
|
Urothelial Cancer
|
RB1 mutation
|
Urothelial Cancer
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
RB1 mutation
|
Bladder Cancer
|
RB1 mutation
|
Bladder Cancer
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
RB1 mutation
|
Small Cell Lung Cancer
|
RB1 mutation
|
Small Cell Lung Cancer
|
nivolumab Resistant: C3 – Early Trials
|
nivolumab Resistant: C3 – Early Trials
|
RB1 mutation
|
Prostate Cancer
|
RB1 mutation
|
Prostate Cancer
|
AST-2970 Resistant: C3 – Early Trials
|
AST-2970 Resistant: C3 – Early Trials
|
RB1 mutation
|
Prostate Cancer
|
RB1 mutation
|
Prostate Cancer
|
docetaxel Resistant: C3 – Early Trials
|
docetaxel Resistant: C3 – Early Trials
|
RB1 mutation
|
Triple Negative Breast Cancer
|
RB1 mutation
|
Triple Negative Breast Cancer
|
carboplatin + docetaxel Sensitive: C3 – Early Trials
|
carboplatin + docetaxel Sensitive: C3 – Early Trials
|
RB1 mutation
|
Ovarian Cancer
|
RB1 mutation
|
Ovarian Cancer
|
carboplatin + paclitaxel Resistant: C3 – Early Trials
|
carboplatin + paclitaxel Resistant: C3 – Early Trials
|
RB1 mutation
|
Prostate Cancer
|
RB1 mutation
|
Prostate Cancer
|
cyclophosphamide + dexamethasone Sensitive: C4 – Case Studies
|
cyclophosphamide + dexamethasone Sensitive: C4 – Case Studies
|
RB1 mutation
|
Meningioma
|
RB1 mutation
|
Meningioma
|
palbociclib Sensitive: D – Preclinical
|
palbociclib Sensitive: D – Preclinical
|
RB1 mutation
|
Ovarian Cancer
|
RB1 mutation
|
Ovarian Cancer
|
abemaciclib Resistant: D – Preclinical
|
abemaciclib Resistant: D – Preclinical
|
RB1 mutation
|
Small Cell Lung Cancer
|
RB1 mutation
|
Small Cell Lung Cancer
|
nivolumab + ipilimumab Resistant: D – Preclinical
|
nivolumab + ipilimumab Resistant: D – Preclinical
|